← Stock Trading Canary · All insider profiles
INSIDER PROFILE · SE
Camilla Öberg
Ekonomichef/finanschef/finansdirektör | Styrelseledamot
Profile key: se|camilla öberg
Purchase history
- Companies traded
- 2
- Purchases · 12M
- 0
- Purchases · 24M
- 3
- Average purchase
- SEK 149,796
- Gross purchase value
- SEK 449,388
- Last purchase
- 2025-07-14
- Completed 20D events
- 3.0
- Outcome status
- INSUFFICIENT_SAMPLE
Latest company: Xvivo Perfusion AB
Companies: Xvivo Perfusion AB | Yubico AB
Post-purchase outcomes
Benchmark-relative outcomes are available against OMX Stockholm 30.
- Excess return = stock return − OMX Stockholm 30 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 3Small sample | 100.0% (3/3) | 66.7% (2/3) | +0.9% | +0.4% | -0.7% |
| 20D | 3Small sample | 100.0% (3/3) | 0.0% (0/3) | -0.7% | -6.2% | -17.1% |
| 60D | 3Small sample | 100.0% (3/3) | 0.0% (0/3) | -20.6% | -22.8% | -27.1% |
| 120D | 3Small sample | 100.0% (3/3) | 0.0% (0/3) | -33.6% | -33.6% | -33.7% |
Research patterns
- First purchase in 12M
- Not classifiable
- Large purchase ≥ €100k
- 0/3
- Cluster buying · 15D
- 1/3
- Buying the dip · ≥20% below prior 52W high
- 3/3
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.